Emil Kakkis, PhD

Title: CEO & President

Organization: Ultragenyx Pharmaceutical

Bio: Dr. Kakkis is best known for his work developing novel treatments for rare diseases and working on policy issues affecting rare disease treatment development through the EveryLife Foundation. Emil is currently CEO, Ultragenyx Pharmaceutical, a company with four approved therapies for rare diseases and 20 different disease treatments in development. Dr. Kakkis has received the Roscoe O Brady Award for innovation from the WORLD and the Henri Termeer Visionary Leader Award.

2021 FUTURES: Gene Therapy & Gene Editing Symposium

Information and updates on the gene therapy and gene editing landscape from experts in the field.

**We experienced a technical issue during this session. Please reach out with questions to Futures@CureDuchenne.org if needed.

Beth Belluscio, MD, PhD

Global Clinical Lead, Rare Neurological Disorders

Pfizer

See more from same speaker

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

See more from same speaker

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

See more from same speaker

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

See more from same speaker

Eric Olson, PhD

Chief Scientific Advisor

Vertex Pharmaceuticals

See more from same speaker

Matthew Pletcher, PhD

Division Head of Gene Therapy Research & Technical Operations

Astellas Gene Therapies

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Genine Winslow, MSc

CEO & President

Chameleon Biosciences

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

2023 FUTURES: Friday Keynote – On the Cutting Edge of Research

The science and research-focused day of FUTURES will begin with an engaging keynote panel featuring key opinion leaders who will discuss the successes, learnings, challenges, and future of this disease space.

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

See more from same speaker

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Dan Levy, MD

VP and Development Head, Rare Neurology Pfizer

See more from same speaker

Carsten Bönnemann, MD

Chief, Neuromuscular and Neurogenetic Disorders of Childhood Section National Institute of Neurological Disorders and Stroke/NIH

See more from same speaker

Kevin Flanigan, MD

Director, Center for Gene Therapy Nationwide Children's Hospital

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years